http://zafgen.com/2025-06-20T02:07:36+00:00http://zafgen.com/patients-families/2024-01-16T12:19:02+00:00http://zafgen.com/docs/default-source/default-document-library/hughes_et_al-2013-obesity.pdf2024-01-16T12:15:16+00:00http://zafgen.com/approach.html2024-01-16T12:13:48+00:00http://zafgen.com/zafgen/our-approach/the-science/2024-01-16T12:10:56+00:00http://zafgen.com/zafgen/newsroom/press-releases/2024-01-16T11:17:21+00:00http://zafgen.com/zafgen/our-approach/zgn-1061/2024-01-16T11:52:01+00:00http://zafgen.com/approach-pipeline.html2024-01-16T12:08:23+00:00http://zafgen.com/zafgen/our-approach/beloranib/2024-01-16T12:06:46+00:00http://zafgen.com/zafgen/our-approach/2024-01-16T12:05:17+00:00http://zafgen.com/our-science-approach/2024-01-16T11:16:01+00:00http://zafgen.com/zafgen/our-approach/unmet-needs-in-prader-willi-syndrome/2024-01-16T11:58:10+00:00http://zafgen.com/zafgen/clinical-trials/2024-01-16T11:56:34+00:00http://zafgen.com/team.html2024-01-16T12:02:45+00:00http://zafgen.com/zafgen/media-library/media-library/2024-01-16T12:27:42+00:00http://zafgen.com/zafgen/newsroom/news-details/2011/01/05/zafgen-announces-positive-topline-phase-1b-data-for-zgn-433-in-obesity/2024-01-16T12:30:03+00:00http://zafgen.com/zafgen/newsroom/news-details/2024-01-16T12:33:16+00:00http://zafgen.com/zafgen/our-approach/beloranib/2024-01-16T12:35:50+00:00http://zafgen.com/zafgen/about-us/2024-01-16T12:43:14+00:00http://zafgen.com/zafgen/about-us/management-team/2024-01-16T12:48:29+00:00